Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care
based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients …

Importance The patterns of disease recurrence after resection of pancreatic ductal
adenocarcinoma with adjuvant chemotherapy remain unclear. Objective To define patterns of …

Background Pre-clinical models demonstrate that platelet activation is involved in the spread
of malignancy. Ongoing clinical trials are assessing whether aspirin, which inhibits platelet …

Background The optimum curative approach to adenocarcinoma of the oesophagus and
oesophagogastric junction is unknown. We aimed to compare trimodality therapy (preoperative …

Background & Aims Most patients with esophageal adenocarcinoma (EAC) present with de
novo tumors. Although this could be due to inadequate screening strategies, the precise …

Background & Aims Esophageal adenocarcinomas (EACs) are heterogeneous and often
preceded by Barrett’s esophagus (BE). Many genomic changes have been associated with …

Background Preclinical, epidemiological, and randomised data indicate that aspirin might
prevent tumour development and metastasis, leading to reduced cancer mortality, particularly …

Objectives To investigate whether screening for malnutrition using the validated malnutrition
universal screening tool (MUST) identifies specific characteristics of patients at risk, in …

Background The prognosis for patients with poorly-differentiated extra-pulmonary neuroendocrine
carcinoma (PD-EP-NEC) is poor. A recognised first-line (1L) treatment for advanced …

Nanotechnology is the engineering of functional systems at the molecular scale which may
exert a revolutionary impact on cancer diagnosis and therapy. Nanotechnology is being …